Bristol Myers Squibb Case Study

Share

Following the EPO’s revocation of the basic dasatinib patent, we had assisted Bristol Myers Squibb (BMS) in successfully defending a crucial secondary patent (EP 1610780), which continued to largely protect their leukaemia treatment, Sprycel, until March 2024.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

We had defended the EP 1610780 patent against attacks by multiple generic companies through various legal instances. On October 4, 2021, the Technical Board of Appeal confirmed the maintenance of the ‘780 patent.

The '780 patent provides about two years more protection than the basic dasatinib patent, including SPCs, would have offered.
Image of Thomas Wolter

Thomas Wolter

Thomas is a Partner in Munich and works primarily in the biopharma sector, mainly with big pharma companies undertaking drug discovery and development. He advises on all stages of a drug’s lifecycle, from initial discovery through clinical trials to regulatory approval. Working closely with in-house IP teams and scientists, he has extensive experience of the prosecution and European opposition and appeal procedures as well as SPCs. He qualified as German and European Patent Attorney in 1999. He has practiced at a German patent law firm before joining Mewburn Ellis in 2020.

Our people

Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.

Our people

Contact Us

We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany. We’d love to hear from you, so please get in touch.

Get in touch